A case report: rapid progression of coronary atherosclerosis in a patient taking Targretin (Bexarotene).
Atherosclerosis
Atypical angina
Cutaneous T-cell lymphoma
Primary hypertriglyceridemia
Targretin (Bexarotene)
Journal
Cardio-oncology (London, England)
ISSN: 2057-3804
Titre abrégé: Cardiooncology
Pays: England
ID NLM: 101689938
Informations de publication
Date de publication:
14 Dec 2020
14 Dec 2020
Historique:
received:
15
09
2020
accepted:
01
12
2020
entrez:
14
12
2020
pubmed:
15
12
2020
medline:
15
12
2020
Statut:
epublish
Résumé
Anti-neoplastic drugs have made major advancements in oncology, however they are not without cardiovascular consequences. We present a patient with cutaneous T-cell lymphoma receiving Targretin therapy who presented with accelerated atherosclerosis. His triglyceride level (TG) was greater than 1000 mg/dL, which rapidly improved with discontinuation of Targretin.
Identifiants
pubmed: 33308287
doi: 10.1186/s40959-020-00087-3
pii: 10.1186/s40959-020-00087-3
pmc: PMC7734706
doi:
Types de publication
Journal Article
Langues
eng
Pagination
31Références
Case Rep Oncol. 2018 Apr 11;11(1):234-238
pubmed: 29805374
Lancet. 2014 Aug 16;384(9943):626-635
pubmed: 25131982
J Am Coll Cardiol. 1997 Jul;30(1):260-311
pubmed: 9207652
JAMA. 2000 Aug 16;284(7):835-42
pubmed: 10938172
Br J Dermatol. 2013 Jan;168(1):192-200
pubmed: 22963233
JAMA Dermatol. 2018 Dec 1;154(12):1424-1431
pubmed: 30422238
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2935-2959
pubmed: 24239921
Neth Heart J. 2008 Jun;16(6):191-6
pubmed: 18665203